Skip to content

Investigation of efficacy of ginger consumption in migraine prophylaxis in patient with migraine

Investigation of efficacy of ginger consumption in migraine prophylaxis in patient with migraine

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200126046263N1
Enrollment
108
Registered
2020-02-18
Start date
2020-02-04
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine. Migraine

Interventions

Intervention 1: Intervention group: Two 500 mg ginger tablets daily for 3 month. Intervention 2: Control group: Two 500 mg placebo tablets daily (containing drug starch) for 3 months.

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 18 to 50 years Migraine history with or without migraine is according to the International Headache Association (IHS) standard, which is at least one year after diagnosis. Diagnosis of mild to severe migraine (defined as the number of headache attacks 2 to 15 times a month, or less frequent and severe attacks that cause a person's disability and disruption in their daily routine).

Exclusion criteria

Exclusion criteria: Non-migraine headaches Allergy to ginger Other neurological diseases (stroke, Alzheimer's, etc.) taking anticoagulants Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Headache. Timepoint: Measurement at baseline (Before the Intervention) and at the end of first and third months after supplementation. Method of measurement: MIDAS.

Secondary

MeasureTime frame
Intensity and frequency. Timepoint: Measurement at baseline (Before the Intervention) and at the end of first and third months after supplementation. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForooh Anjiri Zadeh

Ahvaz University of Medical Sciences

foroogh_anjirizadeh@yahoo.com+98 61 3337 8721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026